Executive Director, US Payer Strategic Accounts

Location: US Field Based

About Summit:

Ivonescimab, also known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).

• HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Overview of Role:

As a key member of the Market Access leadership team, the Executive Director, US Payer Strategic Accounts will help lead the preparation, development, and execution of market access account strategies for a new oncology investigational asset, ivonescimab. This is a critical customer facing role to helping to ensure broad access, reimbursement, and patient affordability. The individual will be responsible for building and maintaining relationships with key stakeholders, including PBMs, National/Regional Plans, Government Channel customers (e.g., Medicaid, VA/DoD), and Pathway organizations. Additionally, the Executive Director, US Payer Strategic Accounts will lead the payer field account team and collaborate closely with sales and key account teams, as well as internal teams, to integrate customer and market insights into pricing, contracting, and market access strategies and plans.

Role and Responsibilities:

• Team Leadership: Build, train, and lead the account management field team (PBM, Plans, State Medicaid, and other Access Stakeholders) to develop and execute strategic business plans that align with overall objectives, maximize product access, and ensure reimbursement.
• Stakeholder Engagement: Establish and maintain relationships with key decision-makers, including Formulary, P&T, and Pathway leaders, Medical & Pharmacy Directors and other population-based stakeholders to secure appropriate access and optimal product positioning.
• Leadership and Influence: Demonstrate leadership among various customer groups and Access stakeholders, including Payers, MACs, Academic Institutions and IDNs, Pathway Committee members, and others (State Societies, COA, NCODA, etc.).
• Cross-functional Collaboration: Partner with internal teams (Market Access, Medical Affairs, HEOR, Regulatory, Legal, Finance, Marketing, Sales, etc.) to address reimbursement challenges and develop coordinated solutions that are compliant and effective.
• Strategy Development: Co-create strategies, tools, and tactics for the field team to communicate the product value proposition effectively. Collaborate on pricing and contracting strategies, HEOR evidence generation plans, patient support programs, payer marketing initiatives, and account management approaches.
• Alignment and Negotiation: Lead discussions with internal and external partners to ensure alignment on access, coverage, and reimbursement strategies.
• Culture and Performance: Foster a high-performance culture within the field team by promoting accountability, urgency, ethical behavior, and professional development.
• Industry Insight: Stay infor